Education
About Us
Working with TipRanks
Follow Us
Oncotelic Therapeutics (OTLC)
OTHER OTC:OTLC
Total Valuation
Oncotelic Therapeutics has a market cap or net worth of $37.71M. The enterprise value is $49.84M.
Market Cap$37.71M
Enterprise Value$49.84M
Share Statistics
Oncotelic Therapeutics has 442,596,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding442,596,600
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Oncotelic Therapeutics’s return on equity (ROE) is -548.25 and return on invested capital (ROIC) is -17388.34%.
Return on Equity (ROE)-548.25
Return on Assets (ROA)-169.58
Return on Invested Capital (ROIC)-17388.34%
Return on Capital Employed (ROCE)-478.24
Revenue Per Employee0.00
Profits Per Employee-25.17K
Employee Count26
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Oncotelic Therapeutics is ―. Oncotelic Therapeutics’s PEG ratio is 0.00007.
PE Ratio―
PS Ratio0.00
PB Ratio1.72
Price to Fair Value1.72
Price to FCF-19.12
Price to Operating Cash Flow-47.49
PEG Ratio0.00007
Income Statement
In the last 12 months, Oncotelic Therapeutics had revenue of 0.00 and earned -4.52B in profits. Earnings per share was -0.01.
Revenue0.00
Gross Profit0.00
Operating Income-3.58B
Pretax Income-4.52B
Net Income-4.52B
EBITDA-3.55M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -704.01K and capital expenditures 0.00, giving a free cash flow of -704.01K billion.
Operating Cash Flow-704.01K
Free Cash Flow-704.01K
Free Cash Flow per Share>-0.01
Dividends & Yields
Oncotelic Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.42
52-Week Price Change142.86%
50-Day Moving Average0.09
200-Day Moving Average0.07
Relative Strength Index (RSI)39.99
Average Volume (3m)410.07K
Important Dates
Oncotelic Therapeutics upcoming earnings date is Apr 20, 2026, TBA (Confirmed).
Last Earnings DateNov 24, 2025
Next Earnings DateApr 20, 2026
Ex-Dividend Date―
Financial Position
Oncotelic Therapeutics as a current ratio of <0.01, with Debt / Equity ratio of 192.39%
Current Ratio<0.01
Quick Ratio<0.01
Debt to Market Cap0.92
Net Debt to EBITDA-3.67
Interest Coverage Ratio-4.17K
Taxes
In the past 12 months, Oncotelic Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Oncotelic Therapeutics EV to EBITDA ratio is -7.66, with an EV/FCF ratio of -36.68.
EV to Sales0.00
EV to EBITDA-7.66
EV to Free Cash Flow-36.68
EV to Operating Cash Flow-36.68
Balance Sheet
Oncotelic Therapeutics has $409.00K in cash and marketable securities with $17.41M in debt, giving a net cash position of -$17.00M billion.
Cash & Marketable Securities$409.00K
Total Debt$17.41M
Net Cash-$17.00M
Net Cash Per Share-$0.04
Tangible Book Value Per Share<$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Oncotelic Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast65.22%